Loading…
Loading…
SOUTH JORDAN, Utah, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that management is scheduled to participate in the following upcoming investor conferences:
Jupiter Topco LLC bought a new position in shares of Merit Medical Systems, Inc. (NASDAQ: MMSI) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 27,531 shares of the medical instruments supplier's stock, valued at approximately $1,908,000. Several other hedge
Hsbc Holdings PLC purchased a new stake in shares of Merit Medical Systems, Inc. (NASDAQ: MMSI) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 5,983 shares of the medical instruments supplier's stock, valued at approximately $414,000. Several
MMSI's broad portfolio, R&D investments and WRAPSODY opportunity support growth, while tariffs, China pressure and competition remain risks.
Freestone Grove Partners LP purchased a new position in Merit Medical Systems, Inc. (NASDAQ: MMSI) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,554 shares of the medical instruments supplier's stock, valued at approximately $1,148,000. Other hedge funds and other
Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.
American Capital Management Inc. acquired a new stake in Merit Medical Systems, Inc. (NASDAQ: MMSI) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 104,967 shares of the medical instruments supplier's stock, valued at approximately $7,278,000. American Capital Management
Merit Medical's growth case is strengthening as launches, acquisitions and therapeutic products broaden its mix, but its premium valuation raises the execution bar.